A new study published in Pharmaceuticals suggests that Osteogenon, an ossein-hydroxyapatite complex, can significantly improve outcomes in patients with lower leg bone fractures treated with the Ilizarov method. The research, conducted between 2021 and 2023, demonstrates that Osteogenon accelerates bone union, reduces complications, and shortens the time to pain relief and return to normal physical activity.
The study involved 26 patients with lower leg bone fractures treated with the Ilizarov method who received Osteogenon, compared to a control group of 25 patients treated with the Ilizarov method alone. Researchers assessed time to bone union, bone union rate, time to resuming normal physical activity, time to achieving pain relief, the number of patients reporting pain relief, and the rate of complications.
Accelerated Bone Union and Recovery
The median time to achieve bone union was significantly shorter in the Osteogenon group (108.5 days) compared to the control group (134 days), with a p-value of <0.001. Bone union was achieved in 100% of the Osteogenon group versus 96% in the control group. Furthermore, the median time to resuming normal physical activity was shorter in the Osteogenon group (22.5 weeks) compared to the control group (27 weeks), p<0.001. Similarly, the median time to achieving pain relief was shorter in the Osteogenon group (21 weeks) compared to the control group (30 weeks), p<0.001.
Reduced Complications
Notably, the number of complications was significantly lower in the Osteogenon group (30.77%) compared to the control group (60%), p=0.035. The proportion of patients who reported pain relief was 88.46% in the group receiving Osteogenon and 76% in the control group; this difference was not statistically significant.
Clinical Implications
These findings suggest that Osteogenon can be a valuable addition to the treatment protocol for lower leg bone fractures using the Ilizarov method. By shortening the time to bone union and reducing complications, Osteogenon may improve patient outcomes and reduce the overall burden of fracture management. The study highlights the potential of ossein-hydroxyapatite complex to enhance bone healing and recovery in orthopedic applications.
